Avenzo Therapeutics Join Forces with DualityBio to Develop AVZO-1418 (DB-1418) for Solid Tumors
Shots:
- Avenzo Therapeutics and DualityBio have signed an exclusive license agreement to develop, manufacture & commercialize the former’s AVZO-1418/DB-1418 across the globe (excl. Greater China)
- As per the terms, DualityBio will get $50M upfront, ~$1.15B development, regulatory and commercial milestones as well as tiered royalties in Avenzo’s territory
- AVZO-1418, an EGFR/HER3-targeting ADC developed using DualityBio's DIBAC platform, showed strong tumor binding affinity & efficacy against in EGFR-resistant/low & HER3-resistant solid tumors. IND-enabling studies are underway, with FIH trial planned in 2025
Ref: Avenzo Therapeutics | Image: BioNTech & Avenzo Therapeutics
Related News:- Moderna's Patent Revoked by the European Patent Office (EPO) due to BioNTech Vaccine Dispute
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
